高级检索
当前位置: 首页 > 详情页

Etiology and management of uveitis-glaucoma-hyphema syndrome: a comprehensive review

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Capital Med Univ, Beijing Tongren Eye Ctr, Beijing Tongren Hosp, Beijing 100730, Peoples R China [2]Minist Ind & Informat Technol, Beijing Key Lab Intraocular Tumor Diag & Treatment, Beijing Ophthalmol & Visual Sci Key Lab, Med Artificial Intelligence Res & Verificat Key La, Beijing 100730, Peoples R China [3]Univ Ottawa, Dept Ophthalmol, Ottawa, ON K1H 8L6, Canada
出处:
ISSN:

关键词: uveitis-glaucoma-hyphema syndrome etiology management

摘要:
center dot The uveitis-glaucoma-hyphema ( UGH) syndrome, initially described in 1978, presents as an iatrogenic complication associated with contact between intraocular implant and ocular tissue. This syndrome encompasses a spectrum of clinical manifestations, including intraocular inflammation, elevated intraocular pressure, and recurrent hemorrhage. Advances in cataract surgery techniques reduced the incidence of early intraocular lens ( IOL) dislocation while inversely increased rates of delayed dislocation. The primary etiology of UGH syndrome is IOL subluxation. Weakness of the ciliary zonules or unstable IOL fixation techniques may predispose the eye to iris-lens contact. Other contributing factors include Soemmering's ring formation, abnormal iris and ciliary body anatomy, positional changes, and improper positioning of glaucoma implants. Clinical examination and imaging modalities such as ultrasound biomicroscopy and anterior segment optical coherence tomography supports diagnosis of UGH. Treatment options range from observation and medical therapies to invasive procedures such as laser therapy, IOL repositioning, or replacement. Endoscopy provides direct visualization for identifying causes intraoperatively, aiding in tailored surgical approaches towards minimal intervention. In conclusion, UGH syndrome poses a complex clinical challenge, emphasizing the importance of understanding its etiology, accurate diagnosis, and personalized management strategies to mitigate its impact on visual function and ensure favorable outcomes.

语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类 | 4 区 医学
小类 | 3 区 眼科学
最新[2025]版:
大类 | 4 区 医学
小类 | 3 区 眼科学
JCR分区:
出版当年[2023]版:
Q2 OPHTHALMOLOGY
最新[2024]版:
Q3 OPHTHALMOLOGY

影响因子: 最新[2024版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版] 出版后一年[2024版]

第一作者:
第一作者机构: [1]Capital Med Univ, Beijing Tongren Eye Ctr, Beijing Tongren Hosp, Beijing 100730, Peoples R China [2]Minist Ind & Informat Technol, Beijing Key Lab Intraocular Tumor Diag & Treatment, Beijing Ophthalmol & Visual Sci Key Lab, Med Artificial Intelligence Res & Verificat Key La, Beijing 100730, Peoples R China
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:28518 今日访问量:0 总访问量:1589 更新日期:2025-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)